Fort Myers, Fla., November 15, 2022 — Florida Cancer Specialists & Research Institute (FCS) welcomes Board-certified medical oncologist Ke Ning, MD to the Sarasota Downtown clinic team. Dr. Ning joined the statewide practice in 2020 and has been serving as a hospitalist in the Sarasota community. He is now providing outpatient cancer care to patients at 1970 Golf St., Sarasota, Florida 34236.
FCS Chief Executive Officer Nathan H. Walcker said, “Dr. Ning is well-known to our patients and colleagues, having served as a hospitalist in the Sarasota community. We are delighted to have him join our team in the FCS Sarasota Downtown clinic.”
FCS President & Managing Physician Michael Diaz, MD adds, “Dr. Ning has provided care for patients throughout all phases of the cancer journey. He will continue to provide our patients with the most advanced and compassionate care.”
Dr. Ning received his medical degree from Ross University School of Medicine in Miramar, Florida. He completed Internal Medicine residency training and a fellowship in Medical Oncology at the University of Florida College of Medicine in Jacksonville.
About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Trained in prestigious medical schools and research institutes, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Founded in 1984, Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.
*Prior to approval
For More Information, Contact:
Michelle Robey, VP of Marketing
Jennifer Bradley, Director of Corporate Communications